5 Key Takeaways
-
1
Merck has acquired the chromatography business of JSR Life Sciences, enhancing its bioprocessing portfolio.
-
2
The acquisition includes Amsphere Protein A resins, crucial for monoclonal antibody manufacturing.
-
3
More than 50 employees and technical expertise in chromatography were integrated into Merck's operations.
-
4
This expansion aims to improve process consistency and support efficient biologics manufacturing.
-
5
Merck's acquisition is designed to accelerate access to critical therapies for customers.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
